Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lirilumab

Bristol-Myers Squibb (BMS) building

BMS to fund hepatitis projects in China and India

Pharma firm awards nine grants to support care for high-risk patients

- PMLiVE

BMS’ daclatasvir scuppered by decision to drop companion drug

FDA denies approval due to discontinuation of asunaprevir development

Bristol-Myers Squibb (BMS) building

BMS takes option to buy fibrosis firm Galecto

The Swedish biotech has a pulmonary fibrosis candidate in early-stage testing

- PMLiVE

BMS expand biologics manufacturing deal with Lonza

Will make wider use of New Hampshire facilities ahead of product launch

Bristol-Myers Squibb (BMS) building

BMS’ PD-1 blocker Opdivo aces lung cancer trial

41% of treated patients alive after 12 months

Bristol-Myers Squibb (BMS) building

BMS taps F-star Alpha for immuno-oncology drug

Drug in development for breast and stomach cancers

- PMLiVE

BMS and Janssen to assess PD1 cancer combination

Will test Opdivo and Imbruvica in non-Hodgkin lymphoma

Bristol Myers Squibb logo

BMS drops US application for ‘breakthrough’ hep C combination

Blames the 'rapidly evolving' market for asunaprevir withdrawal

Bristol Myers Squibb logo

First phase III data for BMS’ anti-PD1 nivolumab

Opdivo shows promise in melanoma study

- PMLiVE

PharmaVentures increases its Asia-Pacific presence

Aki von Roy will be based in Auckland, New Zealand

- PMLiVE

BMS and Pfizer to donate $1m for cardiovascular education

The money will be distributed between seven organisations

Bristol-Myers Squibb (BMS) building

BMS takes PD-1 rivalry with Merck to the law courts

Claims Keytruda infringes antibody patents it holds with Ono Pharmaceutical

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links